

PRESS RELEASE
Epalinges, 09 September 2025

ORYL PHOTONICS CLOSED ITS SERIES A ROUND IN RECORD TIME

ORYL Photonics announces the successful closing of its Series A round. The round was backed by existing shareholders. Their investment commitment has been achieved in record time (two weeks!). This milestone marks a major step forward for the fast-growing Swiss company, which is pioneering advanced solutions for measuring the solubility and aggregation of drug molecules and biologics in the life science sector. The investment will further accelerate the rollout of its recently launched ORYL F1 platform instrument.

"We are thrilled to have successfully closed this funding round, which once again demonstrates the strong confidence our investors have in our vision," shares Orly Tarun, CEO & Co-founder of ORYL Photonics. "With our light-scattering technology, we are committed to rethink solubility and aggregation measurement and set new boundaries – empowering researchers in the pharmaceutical, chemical, and life sciences industries and accelerating their work."

A capital injection for commercialization and scaling up

ORYL Photonics completed its Series A round in July 2025. Founded by Orly Tarun and Nathan Dupertuis in 2020, the startup based in Epalinges launched in May 2025 the **ORYL F1**, a laboratory instrument based on an advanced form of laser-based light scattering technology. The spin-off from EPFL received over the last years more than CHF 4 million in non-dilutive funding, grants, and awards from various organizations such as Innosuisse, the European Innovation Council (EIC), the Fondation pour l'Innovation et la Technologie (FIT), the European Research Commission (ERC), and EPFL. The Series A funding will help ORYL Photonics to commercialize its laboratory instrument, to develop its 'solubility measurement service' offer, and to prepare for its scaling-up.

A technological breakthrough for life science R&D

Measuring how drugs dissolve or aggregate in liquids is crucial for the development of efficient therapeutics. ORYL Photonics closes the gap in solubility measurement with its platform instrument. Based on a proprietary laser-based light scattering technology and the 'Solvent Redistribution method' – born at EPFL – the ORYL F1 is the world's-first solution that disrupts the way solubility and aggregation measurement is performed: with high efficiency (rapid throughput), accuracy, and requiring the least quantity of compounds. It provides a straightforward analysis and an automated testing process for pharmaceutical and biotechnological companies, while saving precious compounds compared to existing technologies.

ABOUT ORYL PHOTONICS

ORYL Photonics is a fast-growing and innovative technology company, a spin-off from [EPFL](#), that aims to be the reference in solubility and aggregation measurement for the life science industry. Applying its proprietary "second harmonic scattering" laser technology, ORYL Photonics has developed a laboratory instrument to measure how drugs dissolve in liquids, providing critical information in R&D and pre-production for pharmaceutical and biotech companies, while saving precious resources.



ORYL Photonics's team in June 2025 (© Kaspar Cottier)

To know more

www.orylphotonics.com

Route de la Corniche 5B

1066 Epalinges, Switzerland

Contact

Dr. Nathan Dupertuis

COO and Co-founder of ORYL Photonics

ndupertuis@orylphotonics.com